Sheller Attorneys 2018 Super Lawyers
Super Lawyers has again recognized the attorneys of Sheller P.C. in 2018. Founder Stephen A. Sheller has been selected by the organization for the fifteenth consecutive year. Attorney Jamie L. Sheller have been awarded the honor multiple years, including 2018. Super Lawyers is a rating service of outstanding lawyers from more than 70 practice areas across […]
Shellers honored as National Liberty Museum’s “2017 Heroes of Liberty”
The National Liberty Museum honored Stephen and Sandra Sheller as “2017 Heroes of Liberty” at the 18th Annual Glass Auction & Gala held on October 7, 2017 at the Sheraton Philadelphia Downtown Hotel. The Shellers were recognized for their support of the Museum and the community through their nonprofit organizations The Sheller Family Foundation and […]
SCOTUS Ruling Increases Risperdal Suits in PA
Risperdal litigation in Philadelphia courts have increased significantly this year and the trend is likely to continue. Mass torts against Janssen, a Johnson & Johnson subsidiary, over it’s antipsychotic drug Risperdal has nearly tripled in Pennsylvania. Plaintiff attorneys say the biggest cause for the recent influx is the expiration of a tolling agreement between Janssen […]
2015 SUPERLAWYERS
The attorneys at Sheller P.C. have been recognized again this year as SuperLawyers. For the twelfth consecutive year, founder Stephen A. Sheller has been selected by the organization and specifically honored as one of the Top 100 attorneys in both Pennsylvania and Philadelphia. (continues below) In addition to Mr. Sheller’s recognition, attorney Jamie L. Sheller have been awarded […]
#1 PA V&S 2013-2014
Sheller, P.C. had the largest settlement in Pennsylvania in 2013-2014 as published in American Lawyer Media’s Legal Intelligencer newspaper. The $2.2 billion settlement with Janssen Pharmaceuticals, a division of Johnson & Johnson, was a qui tam case where Sheller, P.C. represented the whistleblower who brought the qui tam charges. With the U.S. Department of Justice, […]
$7.3M Astellas Pharma Off-Label Marketing and FCA Settlement
Digital Journal 2014-04-16 The whistleblower attorney team of Sheller P.C. announced today that Astellas Pharma U.S., Inc. has agreed to pay $7.3 million to resolve allegations by the Sheller whistleblower client that Astellas violated the False Claims Act by submitting fraudulent claims to government healthcare programs while marketing off-label the antifungal drug Mycamine for use in children. Court […]
